FDA Approval Sought for Frontline Venetoclax Combo in AML
A supplemental New Drug Application has been submitted to the FDA for venetoclax (Venclexta) for use in combination with a hypomethylating agent or low-dose cytarabine for the first-line treatment of patients with acute myeloid leukemia.
Source: OncLive